SGLT2 Inhibitor (Heart Failure)
Drug Safety Update
Please see here for drug safety updates relevant to SGLT2 inhibitors
NICE guidance (See drug specific links below)
Empagliflozin is an option for treating symptomatic chronic heart failure with reduced ejection fraction according to NICE TA773.
In order to ensure clarity for clinicians and promote equitable access, the Kent and Medway Medicines Optimisation Team recommends that:
1. SGLT2 inhibitors (Dapagliflozin & Empagliflozin as per NICE TAs), when used to treat chronic heart failure with preserved, mildly reduced, OR reduced ejection fraction, is initiated by/on the advice of a heart failure specialist, with follow on prescribing in primary care.
2. Where specialist community heart failure teams exist, SGLT2 inhibitors (Dapagliflozin &
Empagliflozin as per NICE TAs) may be initiated by the team following consultation with a
(consultant led) specialist heart failure multidisciplinary team (MDT), with a clear audit trail of
3. For patients with comorbidities e.g., diabetes, multi-speciality MDTs would be appropriate.
4. Monitoring requirements and discontinuation criteria should be set out at initiation and
clearly communicated to the clinician who continues with the prescribing of SGLT2 inhibitors
(Dapagliflozin & Empagliflozin as per NICE TAs).